Results 11 to 20 of about 9,592 (241)

Delivering Effective Hepatitis C Virus Treatment in an Embedded Primary Care Setting Within a Tertiary Care Hospital in Karachi, Pakistan. [PDF]

J Viral Hepat
ABSTRACT Hepatitis C virus (HCV) endemic regions require accessible treatment interventions. Effectiveness and costs of a pilot HCV treatment programme were evaluated at an embedded primary care service within a tertiary care centre at Indus Hospital and Health Network in Karachi, Pakistan.
Shah S, Mafirakureva N, Trickey A, Hasnain A, Khan U, Khowaja S, Ashraf H, Baig-Ansari N, Hickman M, Vickerman P, Walker JG, Lim AG.   +11 more
europepmc   +2 more sources

High Efficiency and Safety of Hepatitis C Treatment Among People Who Inject Drugs in Vietnam. [PDF]

J Viral Hepat
ABSTRACT People who inject drugs (PWID) are highly affected by hepatitis C (HCV) worldwide, particularly in low‐ and middle‐income countries (LMICs), where access to addiction services is often limited. Reducing the burden of HCV, as promoted by WHO, requires effective interventions in this high‐risk population.
Laureillard D, Binh NT, Vinh VH, Hong TT, Quillet C, Thanh NTT, Vallo R, Quynh BTN, Moles JP, Oanh KTH, Huong DT, Rapoud D, Feelemyer J, Michel L, Vickerman P, Fraser H, Weiss L, Lemoine M, Lacombe K, Jarlais DD, Khue PM, Nagot N.   +21 more
europepmc   +2 more sources

Comparative study of four innovative earth-friendly platforms for rapid analysis of daclatasvir dihydrochloride: Application on different matrices

BMC Chemistry, 2023
Background Daclatasvir dihydrochloride has important roles not only in the management of COVID-19 pandemic symptoms but also in the treatment of chronic hepatitis C infection.
Rania A. Sayed, Ahmed R. Mohamed, Wafaa S. Hassan, Manal S. Elmasry   +3 more
doaj   +1 more source

Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients

Journal of Infection in Developing Countries, 2021
Introduction: The conventional interferon therapy of hepatitis C virus has been substituted substantially with sofosbuvir and daclatasvir due to constraints in efficacy and tolerability.
Sonia Younas, Hamid Mukhtar, Umar Farooq Gohar, Abdullah Alsrhani, Badr Alzahrani, Kashaf Junaid, Muhammad Usman Qamar, Hasan Ejaz   +7 more
doaj   +1 more source

Sofosbuvir and daclatasvir [PDF]

British Journal of Clinical Pharmacology, 2016
Chronic hepatitis C infection is a major cause of chronic liver disease, cirrhosis and liver cancer as well as an important indication for liver transplantation. Sofosbuvir (Sovaldi®) 1 and daclatasvir (Daklinza®) 2 are new direct acting antivirals (DAAs) with a favourable safety and tolerability profile, which have significantly changed treatment for ...
Marleen H. M. Hessel, Adam F. Cohen, Robert Rissmann   +2 more
openaire   +2 more sources

Decentralised Hepatitis C Management: A Simplified, Integrated Model of Care in a Primary Health Centre in Pakistan, August 2022-June 2023. [PDF]

J Viral Hepat
ABSTRACT Pakistan has the world's highest hepatitis C virus (HCV) prevalence, yet access to HCV care remains limited. In collaboration with the Ministry of Health Sindh, Médecins Sans Frontières implemented a simplified, decentralised model for HCV screening and treatment at a government‐run primary health centre (PHC) in Baldia Town, Karachi, Pakistan.
Mazzilli S, Aslam MK, Ahmed M, Wailly Y, Miazek M, Ashraf S, Ravji A, de Glanville WA, Isaakidis P.   +8 more
europepmc   +2 more sources

Assessment of the sofosbuvir + daclatasvir (±) ribavirin treatment and the prognostic efficacy of interferon-gamma induced protein 10, macrophage inflammatory-1-beta, and C-reactive protein in Hepatitis C Egyptian patients' therapy outcome

Biomedical and Biotechnology Research Journal, 2022
Background: Hepatitis C virus (HCV) is the most important virus among the infectious agents as the cause of liver disease in Egypt. The aim of this work was to assess the efficacy and tolerability of the sofosbuvir + daclatasvir (±) ribavirin (SOF + DCV [
Hany Mohammed Ibrahim, Faten Roshdy Abdel-Ghaffar, Ahmed Bahgat Zied, Sameha Husni El-Ghareeb   +3 more
doaj   +1 more source

Structure-activity relationships of fluorene compounds inhibiting HCV variants [PDF]

, 2020
Approximately 71 million people suffer from hepatitis C virus (HCV) infection worldwide. Persistent HCV infection causes liver diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma, resulting in approximately 400,000 deaths ...
Gadhe, Changdev G., JANG, SUNG KEY, Keum, Gyochang, Kim, Byeong Moon, Kim, Hee Sun, Kohara, Michinori, Lee, Jae Seung, Moon, Heejo, Mun, Jaegon, Pae, Ae Nim, You, Youngsu   +10 more
core   +1 more source

Antivirals for adult patients hospitalised with SARS-CoV-2 infection: a randomised, phase II/III, multicentre, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX – REVOLUTIOn trialResearch in context

The Lancet Regional Health. Americas, 2023
Summary: Background: Repurposed drugs for treatment of new onset disease may be an effective therapeutic shortcut. We aimed to evaluate the efficacy of repurposed antivirals compared to placebo in lowering SARS-CoV2 viral load of COVID-19 patients ...
Israel S. Maia, Aline Marcadenti, Viviane C. Veiga, Tamiris A. Miranda, Samara P.C. Gomes, Mariana B.S. Carollo, Karina L. Negrelli, Jackeline O. Gomes, Lucas Tramujas, Erlon O. Abreu-Silva, Glauco A. Westphal, Ruthy P. Fernandes, Jacques G.A. Horta, Deborah C. Oliveira, Uri A.P. Flato, Ricardo C.R. Paoliello, Camilo Fernandes, Cássio L. Zandonai, Juliana C. Coelho, Waldemar C. Barros, Juliana C. Lemos, Renata S. Bolan, Marcela M. Dutra, Otavio C.E. Gebara, Ana T.A. Lopes, Meton S. Alencar Filho, Jussara A. Arraes, Victor A. Hamamoto, Mauro E. Hernandes, Nicole A. Golin, Tiago M. Santos, Renato H.N. Santos, Lucas P. Damiani, Fernando G. Zampieri, João Gesto, Flávia R. Machado, Régis G. Rosa, Luciano C.P. Azevedo, Alvaro Avezum, Renato D. Lopes, Thiago M.L. Souza, Otávio Berwanger, Alexandre B. Cavalcanti   +42 more
doaj   +1 more source

Trends in Use of Direct-Acting Antivirals for Treatment of Hepatitis C Virus Infection in Australia 2016-2024. [PDF]

J Viral Hepat
ABSTRACT Direct‐acting antivirals (DAAs) have transformed hepatitis C virus (HCV) treatment in Australia since their inclusion on the Pharmaceutical Benefits Scheme (PBS) in 2016. Treatment has shifted from genotype‐specific to pan‐genotypic regimens, with glecaprevir/pibrentasvir and sofosbuvir/velpatasvir now recommended in clinical guidelines.
Luong CL, Ellett LK, Pratt N, Staff K, Janetzki J.   +4 more
europepmc   +2 more sources